HUP9901562A3 - Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system - Google Patents

Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Info

Publication number
HUP9901562A3
HUP9901562A3 HU9901562A HUP9901562A HUP9901562A3 HU P9901562 A3 HUP9901562 A3 HU P9901562A3 HU 9901562 A HU9901562 A HU 9901562A HU P9901562 A HUP9901562 A HU P9901562A HU P9901562 A3 HUP9901562 A3 HU P9901562A3
Authority
HU
Hungary
Prior art keywords
antibody
cea
conjugates
therapeutic use
monoclonal antibody
Prior art date
Application number
HU9901562A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP9901562A2 publication Critical patent/HUP9901562A2/hu
Publication of HUP9901562A3 publication Critical patent/HUP9901562A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
HU9901562A 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system HUP9901562A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein

Publications (2)

Publication Number Publication Date
HUP9901562A2 HUP9901562A2 (hu) 1999-08-30
HUP9901562A3 true HUP9901562A3 (en) 2000-06-28

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901562A HUP9901562A3 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Country Status (19)

Country Link
US (2) US6277599B1 (ref)
EP (1) EP0896626B1 (ref)
JP (1) JP2000510692A (ref)
CN (1) CN1217750A (ref)
AT (1) ATE350478T1 (ref)
AU (1) AU719513B2 (ref)
BR (1) BR9708910A (ref)
CA (1) CA2250579A1 (ref)
CZ (1) CZ353698A3 (ref)
DE (1) DE69737188T2 (ref)
ES (1) ES2279539T3 (ref)
HU (1) HUP9901562A3 (ref)
IL (1) IL126772A0 (ref)
NO (1) NO985120L (ref)
NZ (1) NZ331978A (ref)
PL (1) PL329871A1 (ref)
SK (1) SK150298A3 (ref)
TR (1) TR199802227T2 (ref)
WO (1) WO1997042329A1 (ref)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO2001036486A2 (en) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
AU752494B2 (en) * 1998-02-25 2002-09-19 Dow Chemical Company, The High affinity humanized ANTI-CEA monoclonal antibodies
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
CA2355402A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Recombinant synthesis of beta-lipotropin and other peptides
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
US20030186384A1 (en) * 2000-04-22 2003-10-02 Stefan Barth Apoptotic agents
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
EP1606387A4 (en) * 2003-03-04 2008-04-23 Alexion Pharma Inc VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS
MXPA05011406A (es) * 2003-04-23 2005-12-12 Medarex Inc Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
WO2005058236A2 (en) * 2003-12-12 2005-06-30 Genencor International, Inc. Cab molecules
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ATE478894T1 (de) * 2004-04-15 2010-09-15 Genencor Int Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
CA2623429C (en) 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
SG11201401518TA (en) 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
KR102066319B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
CN111499750B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高中和活性纳米抗体及其应用
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
CN112867735B (zh) 2018-09-07 2025-05-09 埃泰美德(香港)有限公司 双特异性抗原结合蛋白及其用途
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
EP4021464A4 (en) * 2019-08-27 2024-01-03 The Trustees of The University of Pennsylvania SYNTHETIC CARS TO TREAT IL13Ra2 POSITIVE HUMAN AND CANINE TUMORS
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN115850483B (zh) * 2020-10-21 2025-09-19 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
PL329871A1 (en) 1999-04-12
NZ331978A (en) 2000-05-26
IL126772A0 (en) 1999-08-17
ES2279539T3 (es) 2007-08-16
US6903203B2 (en) 2005-06-07
BR9708910A (pt) 1999-08-03
CA2250579A1 (en) 1997-11-13
HUP9901562A2 (hu) 1999-08-30
CN1217750A (zh) 1999-05-26
TR199802227T2 (xx) 2000-07-21
US6277599B1 (en) 2001-08-21
WO1997042329A1 (en) 1997-11-13
AU2645597A (en) 1997-11-26
DE69737188T2 (de) 2007-10-11
EP0896626B1 (en) 2007-01-03
ATE350478T1 (de) 2007-01-15
US20020142359A1 (en) 2002-10-03
SK150298A3 (en) 1999-04-13
EP0896626A1 (en) 1999-02-17
NO985120D0 (no) 1998-11-03
CZ353698A3 (cs) 1999-02-17
NO985120L (no) 1998-12-29
DE69737188D1 (de) 2007-02-15
JP2000510692A (ja) 2000-08-22
AU719513B2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
HUP9901562A3 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
AU4518196A (en) Adjuvant-incorporated cellular antigens: conjugation and methods
ZA966776B (en) Device in inhalers.
HUP9904177A3 (en) Antibody against human parathormone related peptides
AU696947B2 (en) Monoclonal antibody to oncofetal protein for treating and detecting cancer
ZA9710409B (en) Stable lyophilised pharmaceutical preparations comprising mono- or polyclonal antibodies
AU4648697A (en) Methods and devices for preparing protein concentrates
IL120079A (en) Ultrasound system and cosmetic methods utilizing same
EP0672961A3 (en) Loading element and device.
PL330842A1 (en) Purified superficial sperm antigen, monoclonal antibody therefor and applications associated therewith
EP0805161A4 (en) PROTEIN BINDING (1-3) -BETA-D-GLUCANE, PROTEIN RECOGNIZING ANTIBODIES AND USE OF PROTEIN AND ANTIBODY
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
GB9714971D0 (en) Assays,therapeutic methods and means
GB2329491B (en) Collection and delivery system
IL133536A0 (en) 6-pyrrolidin-2-ylpyridine derivatives, their preparation and application in therapy
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
AU3845395A (en) Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof
AU1135595A (en) Saccharomyces-specific antigens and antibodies, their preparation and use
AU3728595A (en) Antibodies against an extracellular matrix complex and their use in the detection of cancer
AU4499196A (en) Antibodies for use in cancer therapy and diagnosis
GB9419256D0 (en) Antibody and conjugates
FR2735470B1 (fr) Nitrocetones et nitroximes, leur preparation et leur application en therapeutique
SE9503044D0 (sv) Antibodies for use in cancer therapy and diagnosis
EP0596725A3 (en) Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof.